- Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
- Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
- Vaccinex, Inc. Announces Reverse Stock Split
- Vaccinex Announces Pricing of $3.7 Million PIPE Financing
- Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
- Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
As of last trade, Vaccinex Inc (VCNX:NAQ) traded at 6.79, 53.20% above the 52 week low of 4.43 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.16 |
---|---|
High | 7.46 |
Low | 6.50 |
Bid | 6.56 |
Offer | 6.80 |
Previous close | 7.28 |
Average volume | 104.40k |
---|---|
Shares outstanding | 1.58m |
Free float | 1.46m |
P/E (TTM) | -- |
Market cap | 11.53m USD |
EPS (TTM) | -46.02 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 18:07 BST.
More ▼